Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy

Abstract

Toward development of tumor-specific chemotherapy, we designed a new type of liposomes with temperature-triggered drug release and magnetic resonance imaging (MRI) functions.We prepared the multi-functional liposomes by incorporation of thermosensitive poly (2-ethoxy(ethoxyethyl)

Magnetocubosomes for the delivery and controlled release of therapeutics

“…To this purpose, many examples of responsive systems have been proposed, employing specific responsive features of the lipids with respect to the environment of the biological target, i.e. variations in temperature, [14] pH [15] or molecular composition of the media, [16] as triggers for drug release.…”

Application of liposomes in drug development – focus on gastroenterological targets

“…[69][70][71] TSLs can also be engineered to deliver anticancer drugs to tumor tissue and to carry magnetic resonance imaging agent so that drug release can be monitored by MRI signal intensity after being intravenously injected into C26 tumor bearing mice. 72 The search for liposomes with increased ability to mediate intracellular delivery of therapeutics resulted in the development of pH sensitive liposomes, which have potential application in treating digestive tract diseases such as some tumors or inflamed tissues that are more acidic than normal tissues. 73,74 Conventional dioleoyl phosphatidylethanolamine (DOPE) based pH sensitive liposomes achieved longer circulation time and tumor targeted delivery by incorporation of PEG.…”

Multifunctional Polymeric Nanostructures for Therapy and Diagnosis

“…Extensive knowledge has been obtained on the exploitation of these platforms in cancer therapy, particularly their abilities to enhance the efficacy over free drugs through improved drug encapsulation, prolonged circulation half-life, and sustained or triggered drug release [36][37][38]. In addition, preferential accumulation of liposomes and polymeric NPs at the disease sites, as the result of passive targeting through enhanced permeability and retention (EPR) effect and active targeting through selected surface ligands, has been extensively explored [39,40]. As a result, a number of approved therapeutics based on liposomes and polymeric NPs have entered clinical use, and more are under various stages of clinical development [41][42][43][44].…”